Received May 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | — |
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 2 | — | — |
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 3 | — | — |
no adverse event; HCP called to report that a 11 yr old patient received an extra 2nd dose of GARDASIL 9, 18 days after the actual 2nd dose had been administered. First dose of GARDASIL 9 was administered in January 2024, with the 2nd dose being administered on May 1; HCP called to report that a 11 yr old patient received an extra 2nd dose of GARDASIL 9, 18 days after the actual 2nd dose had been administered. First dose of GARDASIL 9 was administered in January 2024, with the 2nd dose being administered on May 1; This spontaneous report was received from a Physician and refers to a 11-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On Jan-2024, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), dose number 1, 0.5 mL (lot # and expiration date were not reported). On 01-May-2025, the patient received a second dose of with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), 0.5 mL (lot # and expiration date were not reported) which was a delayed 2nd dose not administered according to the schedule in the PI (inappropriate schedule of vaccine administered). On 19-May-2025, the patient received a third dose of with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), 0.5 mL (lot # and expiration date were not reported) (inappropriate schedule of vaccine administered). No adverse event was reported.